ELOX Eloxx Pharmaceuticals, Inc.: institutional ownership and insider trading
22 funds reported holding $34.7M of Eloxx Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net bought $34.7M, with 22 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
ELOX revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$4.50M, EPS -0.66
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.75M, EPS -0.86
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.89M, EPS -5.45
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.71M, EPS -4.94
Largest institutional holders of ELOX
- Aberdeen Group plc — $5.55M
- Samsara BioCapital, LLC — $5.55M
- Nantahala Capital Management, LLC — $5.55M
- EcoR1 Capital, LLC — $5.55M
- Siren, L.L.C. — $5.55M
- Stonepine Capital Management, LLC — $5.51M
- VANGUARD CAPITAL MANAGEMENT LLC — $1.09M
- VANGUARD FIDUCIARY TRUST CO — $147K
- SEVEN GRAND MANAGERS, LLC — $139K
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $21.4K
5%+ owners
- Domicilium Capital Partners LLC: 20.0% (Schedule 13G, filed Jun 17, 2026)
- Raymond Debbane: 10.0% (Schedule 13G, filed Jun 15, 2026)
- Nantahala Capital Management, LLC: 9.9% (Schedule 13G, filed Aug 14, 2026)
- Srinivas Akkaraju: 9.9% (Schedule 13G, filed Aug 14, 2026)
- Stonepine Capital Management, LLC: 9.9% (Schedule 13G, filed Jun 16, 2026)
- EcoR1 Capital, LLC: 9.9% (Schedule 13G, filed Jun 16, 2026)